![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: Tamoxifen and centchroman are two non-steroidal, selective estrogen receptors modulators, intended for long term therapy in the woman. Because of their wide spread use, there is a possibility of co-prescription of these agents. Materials & Methods: We studied the probable pharmacokinetic interaction between these agents in breast cancer model rats. A simple, sensitive and rapid LC-ESI-MS/MS method was developed and validated for the simultaneous determination of tamoxifen, centchroman and their active metabolites. Results: The method was linear over a range of 0.2–200 ng/ml. All validation parameters met the acceptance criteria according to regulatory guidelines. Conclusion: LC–MS/MS method for determination of tamoxifen, centchroman and their metabolites was developed and validated. Results show the potential of drug–drug interaction upon co-administration these two marketed drugs.
Financial & competing interests disclosure
The authors also acknowledge Council of Scientific and Industrial Research (CSIR) for providing research fellowship to KSR Raju and I Taneja. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate Institutional Animal Ethical Committee (IAEC) approval from CSIR-Central Drug Research Institute for animal handling procedures and the conduct of the animal experimentations.
Acknowledgements
The authors are thankful to Director, CSIR-CDRI for his constant encouragement and support